Evidence map›Paper›PMID 31888669›Full record

SynthesisRetrovirology2019

An insight to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis; evidence from high-throughput data integration and meta-analysis.

Sayed-Hamidreza Mozhgani, Mehran Piran, Mohadeseh Zarei-Ghobadi, Mohieddin Jafari, Seyed-Mohammad Jazayeri, Talat Mokhtari-Azad, Majid Teymoori-Rad, Narges Valizadeh, Hamid Farajifard, Mehdi Mirzaie and 4 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Retrovirology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  2. Review
  3. Article
  4. Investigating the effect ofIranian journal of microbiology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Sayed-Hamidreza MozhganiDepartment of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Mehran PiranInstituto Gulbenkian de Ciência - IGC, Rua da Quinta Grande, 6, 2780-156, Oeiras, Portugal.
Mohadeseh Zarei-GhobadiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mohieddin JafariResearch Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Seyed-Mohammad JazayeriDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Talat Mokhtari-AzadDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Majid Teymoori-RadDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Narges ValizadehImmunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamid FarajifardImmunology-Microbiology Department, School of Medicine, Qom University of Medical Sciences, 14155-6447, Qom, Iran.
Mehdi MirzaieDepartment of Applied Mathematics, Faculty of Mathematical Sciences, Tarbiat Modares University, Tehran, Iran.
Azam KhamsehDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Houshang RafatpanahImmunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed-Abdolrahim RezaeeImmunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran. rezaeer@mums.ac.ir.
Mehdi NorouziDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. mnorouzi@tums.ac.ir.
Tehran University of Medical Sciences · IRMashhad University of Medical Sciences · IRAlborz University of Medical SciencesInstituto Gulbenkian de Ciência · PTQom University of Medical Science and Health Services · IRTarbiat Modares University · IRUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive disease of the central nervous system that significantly affected spinal cord, nevertheless, the pathogenesis pathway and reliable biomarkers have not been well determined. This study aimed to employ high throughput meta-analysis to find major genes that are possibly involved in the pathogenesis of HAM/TSP.

resultsHigh-throughput statistical analyses identified 832, 49, and 22 differentially expressed genes for normal vs. ACs, normal vs. HAM/TSP, and ACs vs. HAM/TSP groups, respectively. The protein-protein interactions between DEGs were identified in STRING and further network analyses highlighted 24 and 6 hub genes for normal vs. HAM/TSP and ACs vs. HAM/TSP groups, respectively. Moreover, four biologically meaningful modules including 251 genes were identified for normal vs. ACs. Biological network analyses indicated the involvement of hub genes in many vital pathways like JAK-STAT signaling pathway, interferon, Interleukins, and immune pathways in the normal vs. HAM/TSP group and Metabolism of RNA, Viral mRNA Translation, Human T cell leukemia virus 1 infection, and Cell cycle in the normal vs. ACs group. Moreover, three major genes including STAT1, TAP1, and PSMB8 were identified by network analysis. Real-time PCR revealed the meaningful down-regulation of STAT1 in HAM/TSP samples than AC and normal samples (P = 0.01 and P = 0.02, respectively), up-regulation of PSMB8 in HAM/TSP samples than AC and normal samples (P = 0.04 and P = 0.01, respectively), and down-regulation of TAP1 in HAM/TSP samples than those in AC and normal samples (P = 0.008 and P = 0.02, respectively). No significant difference was found among three groups in terms of the percentage of T helper and cytotoxic T lymphocytes (P = 0.55 and P = 0.12).

conclusionsHigh-throughput data integration disclosed novel hub genes involved in important pathways in virus infection and immune systems. The comprehensive studies are needed to improve our knowledge about the pathogenesis pathways and also biomarkers of complex diseases.

Indexed as

Gene ExpressionData Interpretation, StatisticalGene Regulatory NetworksHigh-Throughput Screening AssaysHumansHuman T-lymphotropic virus 1Microarray AnalysisParaparesis, Tropical SpasticProvirusesT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerViral LoadHAM/TSPHigh-throughput data integrationHTLV-1HTLV-1-associated myelopathy/tropical spastic paraparesisMeta-analysisMicroarray

Identifiers

PMID31888669
PMCPMC6937958
OpenAlexW2998384989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.